Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press98710.17650/1726-9776-2019-15-3-89-101DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железыNew possibilities of combined antiandrogen therapy in patients with metastatic hormone-sensitive prostate cancerНовые возможности комбинированной антиандрогенной терапии больных метастатическим гормоночувствительным раком предстательной железыhttps://orcid.org/0000-0002-1353-2271AlekseevB. Ya.АлексеевБ. Я.
Russian Federation

Борис Яковлевич Алексеев

249031 Обнинск, ул. Королева, 4

byalekseev@mail.ruNational Medical Research Radiological Center, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России30092019153891010810201908102019https://oncourology.abvpress.ru/oncur/article/view/987

Currently, enzalutamide is the standard of pharmaceutical therapy of metastatic and non-metastatic castration-resistant prostate cancer. However, until recently there was no data on effectiveness and safety of enzalutamide in metastatic hormone-sensitive prostate cancer. Results of 2 large randomized clinical trials ARCHES and ENZAMET showed that early prescription of enzalutamide in combination with standard androgen deprivation therapy allows to significantly increase survival of patient with metastatic hormone-sensitive prostate cancer. The review describes data of these trials and advisability of prescribing enzalutamide in combination with androgen deprivation therapy as 1st line therapy of metastatic hormone-sensitive prostate cancer.

В настоящее время препарат энзалутамид является стандартом лекарственной терапии при метастатическом и неметастатическом кастрационно-резистентном раке предстательной железы. При этом до недавнего времени отсутствовали данные по эффективности и безопасности энзалутамида при метастатическом гормоночувствительном раке предстательной железы. Результаты 2 крупных рандомизированных исследований ARCHES и ENZAMET продемонстрировали, что раннее назначение энзалутамида в комбинации со стандартной андрогендепривационной терапией позволяет значительно увеличить выживаемость больных метастатическим гормоночувствительным раком предстательной железы. В представленном обзоре освещены данные этих исследований и целесообразность назначения энзалутамида в комбинации с андрогендепривационной терапией в качестве 1-й линии терапии метастатического гормоночувствительного рака предстательной железы.

metastatic hormone-sensitive prostate cancerhormone therapyenzalutamideметастатический гормоночувствительный рак предстательной железыгормональная терапияэнзалутамид1. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. DOI: 10.1056/NEJMoa040720.Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. DOI: 10.1056/NEJMoa040720.2. Ryan C.J., Smith M.R., de Bono J.S. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 10;368(2):138–48.Ryan C.J., Smith M.R., de Bono J.S. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 10;368(2):138–48.3. Beer T.M., Armstrong A.J., Rathkopf D.E. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424–33. DOI: 10.1056/NEJMoa1405095.Beer T.M., Armstrong A.J., Rathkopf D.E. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424–33. DOI: 10.1056/NEJMoa1405095.4. Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187–97. DOI: 10.1056/NEJMoa1207506.Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187–97. DOI: 10.1056/NEJMoa1207506.5. Fizazi K., Scher H.I., Molina A. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, doubleblind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10):983–92. DOI: 10.1016/S1470-2045(12)70379-0.Fizazi K., Scher H.I., Molina A. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, doubleblind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10):983–92. DOI: 10.1016/S1470-2045(12)70379-0.6. de Bono J.S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147–54. DOI: 10.1016/S0140-6736(10)61389-X.de Bono J.S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147–54. DOI: 10.1016/S0140-6736(10)61389-X.7. Parker C., Nilsson S., Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213–23. DOI: 10.1056/NEJMoa1213755.Parker C., Nilsson S., Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213–23. DOI: 10.1056/NEJMoa1213755.8. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Prostate Cancer Trialist’s Collaborative Group. Lancet 2000;355:1491–8.Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Prostate Cancer Trialist’s Collaborative Group. Lancet 2000;355:1491–8.9. Kyriakopoulos C.E., Chen Y.H., Carducci M.A. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36(11):1080–7. DOI: 10.1200/JCO.2017.75.3657.Kyriakopoulos C.E., Chen Y.H., Carducci M.A. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36(11):1080–7. DOI: 10.1200/JCO.2017.75.3657.10. James N.D., Sydes M.R., Clarke N.W. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387(10024):1163–77. DOI: 10.1016/S0140-6736(15)01037-5.James N.D., Sydes M.R., Clarke N.W. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387(10024):1163–77. DOI: 10.1016/S0140-6736(15)01037-5.11. Fizazi K., Tran M.P., Fein L. et al. Abiraterone acetate and prednisone in patients with newly diagnosed high risk metastatic castrate-sensitive prostate cancer (LATTITUDE) final overall survival analysis of a randomized, double-blind, phase 3 trial. Lancet 2019;5:686–700.Fizazi K., Tran M.P., Fein L. et al. Abiraterone acetate and prednisone in patients with newly diagnosed high risk metastatic castrate-sensitive prostate cancer (LATTITUDE) final overall survival analysis of a randomized, double-blind, phase 3 trial. Lancet 2019;5:686–700.12. James N.D., de Bono I.S., Spears M.R. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377(4):338–51. DOI: 10.1056/NEJMoa1702900.James N.D., de Bono I.S., Spears M.R. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377(4):338–51. DOI: 10.1056/NEJMoa1702900.13. Hussain M., Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castrate-resistant prostate cancer. N Engl J Med 2018;378:2465–74.Hussain M., Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castrate-resistant prostate cancer. N Engl J Med 2018;378:2465–74.14. Armstrong A.J., Szmulewitz R.Z., Petrylak D.P. et al. ARCHES: a randomized phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019. DOI: 10.1200/JCO.19.00799.Armstrong A.J., Szmulewitz R.Z., Petrylak D.P. et al. ARCHES: a randomized phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019. DOI: 10.1200/JCO.19.00799.15. Davis I.D., Martin A.J., Stockler M.R. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381(2):121–31. DOI: 10.1056/NEJMoa1903835.Davis I.D., Martin A.J., Stockler M.R. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381(2):121–31. DOI: 10.1056/NEJMoa1903835.